Alterity Therapeutics' (ASX: ATH) phase 2 clinical trial nears, commercialisation plans continue for MSA drug (w/ David Stamler)

Alterity Therapeutics (ASX: ATH) chief executive officer Dr David Stamler joins Small Caps to discuss the company's lead drug candidate ATH434, which has been developed to combat the side effects of Parkinsonian disorders. The disorder includes multiple system atrophy (MSA), which Alterity is focused on treating with ATH434 in clinical trials. Dr Stamler points out there is a substantial unmet need for MSA treatments with forecast potential annual sales of ATH434 in the US of $550-725 million.